IMF Gala Raises Over $675,000 to Fight Myeloma

The International Myeloma Foundation (IMF) raised over $675,000 at its 15th annual gala, earmarked for research and educational initiatives to combat myeloma. The event, attended by celebrities and industry leaders, honored organizations for their contributions to myeloma research and patient support. The funds will specifically support the Peter Boyle Research Fund, the Black Swan Research Initiative, and programs addressing health disparities for those with myeloma.

International Myeloma Foundation Gala Raises Over $675,000 for Myeloma Research and Education

The International Myeloma Foundation (IMF) held its 15th annual gala in New York City in April, raising over $675,000 for groundbreaking myeloma research and educational initiatives. The event, recognized as a testament to the collective efforts and unwavering dedication of the myeloma community, was a resounding success.

"This gala is a celebration of our shared purpose and determination to conquer myeloma," remarked Yelak Biru, President and CEO of the IMF. "We unite patients, caregivers, researchers, doctors, supporters, and industry partners, guided by our unwavering commitment to finding a cure."

Highlighting the significance of research funding, Biru emphasized that "science and research require financial support, without which finding a cure for myeloma remains an elusive goal." The gala's success brings the IMF closer to its aspirations of advancing myeloma research and accelerating the path towards a definitive cure.

The event was graced by renowned actor and comedian Ray Romano, along with esteemed guest appearances by Tony Danza, Robert Klein, Patricia Heaton, and Alex Meneses. The evening served as a platform to honor the Peter Boyle Research Fund, established in memory of the actor who succumbed to myeloma, and the contributions it makes to advancing myeloma research.

"We have made significant strides in myeloma through collaborative efforts between researchers, pharmaceutical companies, patients, and non-profit foundations," stated S. Vincent Rajkumar, MD, Chairman of the Board for the IMF. "The IMF's 15th Annual Gala celebrates these advancements and reinforces our unwavering commitment to ongoing research and patient support."

Several organizations were acknowledged for their invaluable contributions to myeloma research. The IMF Diversity, Equity, and Inclusion Award, recognizing efforts to address health disparities, was bestowed upon Johnson & Johnson. Tyrone Brewer, President of U.S. Hematology at Johnson & Johnson, expressed the company's dedication to ensuring equitable access to care and health outcomes regardless of individual circumstances.

The Partner of the Year Award honored LatentView Analytics for its partnership with the IMF in streamlining the process from diagnosis to treatment, facilitating the timely initiation of therapy and improving patient outcomes. Rajan Sethuraman, CEO of LatentView, expressed gratitude for the recognition and highlighted the collaboration's positive impact on patient lives.

The IMF Innovation Award recognized the contributions of Bristol Myers Squibb and 2seventy bio in developing Abecma (idecabtagene vicleucel), a CAR T-cell therapy that has expanded approval for patients with hard-to-treat myeloma. The EU and other regulatory authorities have followed suit, demonstrating the potential of CAR T-cell therapies in addressing this challenging disease.

Carvykti (ciltacabtagene autoleucel), a BCMA-targeting CAR T-cell therapy developed by Janssen and Legend Biotech, has also recently received expanded approval in the U.S. and EU as a second-line treatment for relapsed or refractory multiple myeloma. This regulatory decision broadens the treatment options available to patients with progressive disease.

The IMF's 15th Annual Gala stands as a testament to the tireless efforts and unwavering support of individuals and organizations committed to conquering myeloma. The funds raised will fuel groundbreaking research, foster educational initiatives, and empower patients with the knowledge and resources necessary to navigate their myeloma journey. As the search for a cure continues, the IMF remains steadfast in its mission to improve the lives of those affected by myeloma.